“It’s easy to say because of the profusion of [CBD on the market] that it’s all witchcraft or snake oil, but that’s not the case,” Russo said. “CBD is a very versatile medicine that hasn’t gotten the attention it deserves over the decades.”
If you’re taking CBD to help with anxiousness or pain and it works, that in itself may help you get more rest.
You may feel less anxiety.
The other tricky part is that there haven’t been enough clinical studies conducted with CBD yet. And while there are plenty of anecdotal studies out there, this can make it difficult for physicians to educate both themselves and patients about CBD.
“CBD won’t completely take the pain away like a morphine would,” Khare said, “but it may decrease it to a point where it makes the pain more tolerable.”
According to Dr. Rahul Khare, founder of Innovative Express Care in Chicago, CBD attaches indirectly to cannabinoid receptors in the body (these are responsible for a variety of functions throughout the body such as appetite, pain sensation, mood and memory). This process can also help decrease inflammation. In turn, CBD may help reduce chronic pain for some people.
 Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017 Jul;175:133–50.
- Based on currently available science, InsideTracker cannot recommend with certainty that you will benefit from recreational CBD use.
- The science does look promising, and clinical trials investigating the impact of CBD are underway.
- Based on preliminary evidence, CBD may reduce anxiety, particularly in individuals with social anxiety.
- CBD may reduce pain in individuals with chronic pain and reduce symptoms of frequent opioid consumption.
- CBD may impart anti-inflammatory effects.
Evidence-based tools to empower you to live a healthier, longer life.
 Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010.
Michelle is a Nutrition Science Intern at InsideTracker. Complete with her dietetic internship, you’ll find Michelle analyzing the research behind recent nutrition trends to inform novel food and supplement recommendations.
Alternatively, CBD binds to CB1 and CB2 at a much slower rate than Δ9-THC, which results in the activation of similar physiological processes without the psychoactive or “high” effects. These physiologic effects make CBD promising for clinical benefits, many of which have been tested in small-scale trials and evaluated in systematic reviews over recent years. Now, let’s get into those results and summarizing what we know so far.
 Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011 Nov;72(5):735–44.
Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. 2020;61(2):267-277. View abstract.
Brady CM, DasGupta R, Dalton C, et al. An open-label study of cannabis-based extracts for bladder dysfuntion in advanced multiple sclerosis. Mult Scler 2004;10(4):425-33. View abstract.
Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010;13(4):421-32. View abstract.
Possibly Effective for
Zuardi AW, Rodriguez JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991;104(2):260-4. View abstract.
Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant. 2019;19(10):2944-2948. View abstract.
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., and Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp.Ther. 2004;308(3):838-845. View abstract.
Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019 Jan-Feb;41(1):9-14. Epub 2018 Oct 11. View abstract.